Abstract
Hypertension is a major risk factor for stroke and many patients with acute stroke have elevated blood pressures. The management of hypertension in the setting of acute ischaemic stroke remains a source of confusion and controversy. Lowering blood pressure in this setting may be hazardous because of impaired cerebral autoregulation. Treatment may be considered in patients who are otherwise candidates for thrombolytic therapy, patients who have severe hypertension or patients who have specific concomitant medical conditions including acute myocardial infarction, aortic dissection, hypertensive encephalopathy, or severe left ventricular failure. In choosing an agent for acute treatment, drugs that can produce a precipitous decline in blood pressure (e.g. sublingual calcium antagonists) should be avoided. Drugs with the capacity to dilate cerebral vessels should be used with caution as they have the potential to increase intracranial pressure. Long term management of hypertension in poststroke patients is often required. The potential for certain classes of drugs (e.g. α2-adrenergic receptor agonists and α1-adrenergic receptor antagonists) to impair the recovery process should be considered when choosing an antihypertensive for treatment of these patients.
Original language | English |
---|---|
Pages (from-to) | 13-18 |
Number of pages | 6 |
Journal | Drug Safety |
Volume | 22 |
Issue number | 1 |
DOIs | |
State | Published - 2000 |
Bibliographical note
Funding Information:Duke Center for Cerebrovascular Disease, Stroke Policy Program, Center for Clinical Health Policy Research, Duke University and Durham Veterans Administration Medical Center, Durham, North Carolina, USA
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Pharmacology (medical)